Kancera reports results from analyses of the Fractalkine system in lymphoma patients’ immune cells


This is a translation of a press release in Swedish 2019-01-29

Kancera AB (Nasdaq First North: KAN) today announces that the results of a study of lymphoma patients’ immune cells show that the Fractalkine system is activated in the cancers of chronic lymphocytic leukemia, diffuse large-cell B cell lymphoma and Hodgkin’s lymphoma. In view of this discovery, the company will now deepen the investigations into how drug candidates that interact with the Fractalkine system, such as KAND567, may play a role in future treatments of these diseases.

KAND567 acts by blocking the Fractalkine receptor. The receptor is an important player in the inflammatory process and a promising target for new and more selective anti-inflammatory drugs. Scientific studies have demonstrated elevated levels of Fractalkine in cardiovascular diseases, inflammatory diseases and various forms of cancer. In the second half of 2019, Kancera plans to start a Phase IIa study with the drug candidate in patients suffering from a myocardial infarction, but will also evaluate the possibilities of taking the project further in the cancer area.

The now completed study aimed to investigate whether the fractalkine system is activated and possibly induced in patients suffering from lymphoma. The results, which include analysis of immune cells in the blood from 66 patients, show that there is a statistically significant activation of the fractalkine system in the lymphoma patients compared to a group of healthy controls. The study has been carried out by researchers at Karolinska Institutet in collaboration with Kancera.

Based on these promising research results, Kancera has decided to deepen its laboratory studies with the goal of determining whether drug candidates that interact with the Fractalkine system, such as KAND567, have the potential to develop into an improved treatment for lymphoma. These follow-up studies are expected to be completed during the third quarter of 2019.

“Due to its mechanism of action, KAND567 has the possibility of influencing a number of disease states. We expect to initiate a Phase II study later this year to evaluate the possibility of limiting the damage to the heart muscle of infarct patients, but the results of the now completed study support continued studies of whether drugs directed against the Fractalkine system can also develop as a potential new treatment for lymphoma, ”says Thomas Olin, President and CEO, Kancera AB.

About Kancera
Kancera develops the basis for new therapeutics, starting with new treatment concepts and ending with the sale of a drug candidate to international pharmaceutical companies. Kancera is currently developing drugs for the treatment of inflammation and cancer, by regulating the immune system, blocking survival signals in the cancer cell and addressing repair mechanisms. Kancera’s operations are based in the Karolinska Institute Science Park in Stockholm and the company employs around 15 people. Kancera shares are traded on NASDAQ First North and the number of shareholders was more than 7400 as of September 30th, 2018. FNCA is Kancera’s Certified Adviser. MD PhD Charlotte Edenius, MD PhD Anders Gabrielsen, Professor Carl-Henrik Heldin samt Professor Håkan Mellstedt are board members and Kancera’s scientific advisers.

For further information, contact:

Thomas Olin, CEO: +46-(0)735-20 40 01

Kancera AB (publ)
Karolinska Institutet Science Park
Banvaktsvägen 22
SE 171 48 Solna

Welcome to visit our home-page; www.kancera.com